Are biosimilars effective and will they expand treatment options for patients? Posted: June 20, FDA approved pembrolizumab for patients with solid tumors that have specific genetic features, called mismatch repair deficiency and high microsatellite instability.
Posted: June 29, The NCI Experimental Therapeutics NExT program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to human clinical trials.
Posted: July 21, The FDA has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy called the DigniCap Scalp Cooling System—for use by patients with any type of solid tumor. Posted: December 1, People with HIV are often excluded from clinical trials to protect their safety.
The findings could be the basis for developing new treatments for patients with cancer who develop gastrointestinal side effects from chemotherapy.
The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a Posted: February 5, Using mouse models of cancer, researchers found that altering the gut microbiome could affect whether tumors responded to checkpoint inhibition. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists.
Experiments in mice suggested that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors. Posted: August 11, A drug used to treat several blood cancers, ibrutinib, has been approved by FDA to treat chronic graft-versus-host disease, making it the first approved therapy for this potentially fatal side effect of cancer-related stem cell transplants.